Mechanism of Panlongqi Tablets intervening in vertebral artery type of cervical spondylosis in rats through PI3K/AKT signaling pathway based on network pharmacology and experimental verification.
10.19540/j.cnki.cjcmm.20220302.701
- Author:
Rui-Rui MING
1
;
Yan-Qiong ZHANG
1
;
Ying XU
1
;
Teng-Teng XU
1
;
Luo-Chang-Ting FANG
1
;
Jin-Xia WANG
1
;
Xiao-Xiao WANG
1
;
Zhi-Xing HU
1
;
Chao YANG
1
;
Ke-Xin JIA
1
;
Lu WANG
1
;
Chun-Fang LIU
1
;
Na LIN
1
Author Information
1. Institute of Chinese Materia Medica, China Academy of Chinese Medicine Sciences Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Panlongqi Tablets;
inflammatory pathways;
network pharmacology;
vertebral artery type of cervical spondylosis
- MeSH:
Animals;
Drugs, Chinese Herbal;
I-kappa B Kinase/pharmacology*;
NF-kappa B/metabolism*;
Network Pharmacology;
Phosphatidylinositol 3-Kinases/metabolism*;
Protein Serine-Threonine Kinases;
Proto-Oncogene Proteins c-akt/metabolism*;
Rats;
Signal Transduction;
Spondylosis/drug therapy*;
Tumor Necrosis Factor-alpha/metabolism*;
Vascular Endothelial Growth Factor A/genetics*;
Vertebral Artery/metabolism*
- From:
China Journal of Chinese Materia Medica
2022;47(16):4454-4461
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to further explore the relevant mechanism of action by network pharmacology integrated with animal experimental verification based on previous proven effective treatment of vertebral artery type of cervical spondylosis(CSA) by Panlongqi Tablets. Bionetwork analysis was performed to establish drug-disease interaction network, and it was found that the key candidate targets of Panlongqi Tablets were enriched in multiple signaling pathways related to CSA pathological links, among which phosphatidylinositol 3-kinase(PI3 K)/serine-threonine kinase(AKT/PKB) signaling pathway was the most significant. Further, mixed modeling method was used to build the CSA rat model, and the rats were divided into normal, model, Panlongqi Tablets low-, medium-and high-dose(0.16, 0.32, 0.64 g·kg~(-1)) and Jingfukang Granules(positive drug, 1.35 g·kg~(-1)) groups. After successful modeling, the rats were administered for 8 consecutive weeks. Pathological changes of rat cervical muscle tissues were detected by hematoxylin-eosin(HE) staining, and the content of interleukin-1β(IL-1β), tumor necrosis factor-α(TNF-α), vascular endothelial cell growth factor(VEGF) and chemokine(C-C motif) ligand 2(CCL2) in rat serum and/or cervical tissues was determined by enzyme-linked immunosorbent assay(ELISA). Western blot was employed to detect the protein expression levels of chemokine(C-C motif) receptor 2(CCR2), PI3 K, AKT, phosphorylated AKT(p-AKT), I-kappa-B-kinase beta(IKK-beta/IKKβ), nuclear factor kappa B(NF-κB P65) and phosphorylated nuclear factor kappa B(NF-κB p-P65) in rat cervical tissues, and positive expression of p-NF-κB P65 in rat cervical muscle tissues was detected by immunofluorescence. The results showed that Panlongqi Tablets at different doses improved the degree of muscle fibrosis and inflammation in cervical muscle tissues of CSA rats, and reduced the content of inflammatory factors IL-1β, TNF-α, VEGF, CCL2 and CCR2 in serum and/or cervical tissues. The protein expression levels of PI3 K, p-AKT, IKKβ and p-NF-κB P65 as well as the nuclear entry of p-NF-κB P65 in cervical tissues were down-regulated. These findings suggest that Panlongqi Tablets can significantly inhibit the inflammatory response of CSA rats, and the mechanism of action may be related to the down-regulation of the activation of PI3 K/AKT signaling pathway.
